Brief: Innocan Pharma Initiates FDA Approval Process For Liposome Injection Therapy For Chronic Pain
22/04/2024 21:10
April 22 (Reuters) - Innocan Pharma Corp INNO.CD :
* INNOCAN PHARMA INITIATES FDA APPROVAL PROCESS FOR LIPOSOME
INJECTION THERAPY FOR CHRONIC PAIN
Source text for Eikon: ID:nCNWH7wzSa
Further company coverage: INNO.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Innocan Pharma
See all newsBrief: Innocan Pharma Corp To Offer Up To 3.75 Million Units In IPO - SEC Filing
Brief: Innocan Pharma Announces Promising Results Of LPT-CBD Administered To Gottingen Minipigs
Brief: Innocan Pharma Corp - Liposomal Cbd Injection Technology Patent Allowed In Japan
Brief: Innocan Pharma Corp Now Sees U.S IPO Of 1.1 Million Units - SEC Filing
Brief: Innocan Pharma Announces Details Of Proposed Share Consolidation